Coya Therapeutics (COYA) Operating Income (2022 - 2026)
Coya Therapeutics (COYA) posted Operating Income of -$7.6 million for Q1 2026, down 26.68% sequentially from -$6.0 million in Q4 2025, and little changed YoY from -$7.6 million in Q1 2025.
Coya Therapeutics (COYA) Operating Income (2022 - 2026) Analysis & Trends
Coya Therapeutics has reported Operating Income for 5 years, with the latest figure at -$7.6 million in Q1 2026.
- Quarterly Operating Income changed 0.48% year-over-year to -$7.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$22.5 million (down 15.81% YoY) and the FY2025 annual result came in at -$22.6 million, down 30.76% from the prior year.
- Operating Income fell to -$7.6 million in Q1 2026 per COYA's latest filing, from -$6.0 million in the prior quarter.
- Over five years, Operating Income peaked at $1.8 million in Q4 2023 and troughed at -$7.7 million in Q1 2025.
- A 5-year average of -$3.8 million and a median of -$3.4 million in 2022 frame the typical range for Operating Income.
- The sharpest annual moves came in 2023 and 2024: Operating Income jumped 190.6% in 2023, then sank 324.79% in 2024.
- Over 5 years, Operating Income stood at -$2.0 million in 2022, then surged by 190.6% to $1.8 million in 2023, then sank by 324.79% to -$4.1 million in 2024, then tumbled by 47.81% to -$6.0 million in 2025, then fell by 26.68% to -$7.6 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$7.6 million, -$6.0 million, and -$2.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Coya Therapeutics | 113.30 Mn | 70.10 Mn | - | -7.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.05 Mn |
| Mar 31, 2026 | -7.64 Mn |
| Dec 31, 2025 | -6.03 Mn |
| Sep 30, 2025 | -2.43 Mn |
| Jun 30, 2025 | -6.41 Mn |
| Mar 31, 2025 | -7.68 Mn |
| Dec 31, 2024 | -4.08 Mn |
| Sep 30, 2024 | -4.45 Mn |
| Jun 30, 2024 | -3.24 Mn |
| Mar 31, 2024 | -5.48 Mn |
| Dec 31, 2023 | 1.82 Mn |
| Sep 30, 2023 | -3.56 Mn |
| Jun 30, 2023 | -3.25 Mn |
| Mar 31, 2023 | -2.90 Mn |
| Dec 31, 2022 | -2.00 Mn |
| Sep 30, 2022 | -2.66 Mn |
| Jun 30, 2022 | -3.45 Mn |
| Mar 31, 2022 | -1.70 Mn |